[go: up one dir, main page]

MA32723B1 - Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments - Google Patents

Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments

Info

Publication number
MA32723B1
MA32723B1 MA33786A MA33786A MA32723B1 MA 32723 B1 MA32723 B1 MA 32723B1 MA 33786 A MA33786 A MA 33786A MA 33786 A MA33786 A MA 33786A MA 32723 B1 MA32723 B1 MA 32723B1
Authority
MA
Morocco
Prior art keywords
anilino
drugs
preparation
sulfoximine
marked
Prior art date
Application number
MA33786A
Other languages
Arabic (ar)
English (en)
Inventor
Ulrich Lücking
Rolf Jautelat
Gerhard Siemeister
Julia Schulze
Philip Lienau
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA32723B1 publication Critical patent/MA32723B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION PORTE SUR DES DÉRIVÉS D'ANILINO-PYRIMIDINE À SUBSTITUTION SULFOXIMINE DE FORMULE (I), SUR DES PROCÉDÉS POUR LES PRÉPARER, AINSI QUE SUR LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE DIFFÉRENTES MALADIES.
MA33786A 2008-10-21 2011-04-20 Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments MA32723B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (fr) 2008-10-21 2008-10-21 Dérivés d'anilino-pyrimidine substitués par sulfoximine en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
PCT/EP2009/007247 WO2010046035A1 (fr) 2008-10-21 2009-10-09 Dérivés d'anilino-pyrimidine à substitution sulfoximine en tant qu'inhibiteurs de cdk, leur préparation et leur utilisation comme médicaments

Publications (1)

Publication Number Publication Date
MA32723B1 true MA32723B1 (fr) 2011-10-02

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33786A MA32723B1 (fr) 2008-10-21 2011-04-20 Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments

Country Status (38)

Country Link
US (1) US8735412B2 (fr)
EP (2) EP2179991A1 (fr)
JP (1) JP5564054B2 (fr)
KR (1) KR20110069115A (fr)
CN (1) CN102197029B (fr)
AR (1) AR074053A1 (fr)
AU (1) AU2009306733C1 (fr)
BR (1) BRPI0920112A2 (fr)
CA (1) CA2739739C (fr)
CO (1) CO6361926A2 (fr)
CR (1) CR20110210A (fr)
CU (1) CU24052B1 (fr)
CY (1) CY1115590T1 (fr)
DK (1) DK2350026T3 (fr)
DO (1) DOP2011000107A (fr)
EA (1) EA019230B1 (fr)
EC (1) ECSP11010992A (fr)
ES (1) ES2499028T3 (fr)
HN (1) HN2011001019A (fr)
HR (1) HRP20140830T1 (fr)
IL (1) IL211713A (fr)
MA (1) MA32723B1 (fr)
MX (1) MX2011004238A (fr)
MY (1) MY155230A (fr)
NZ (1) NZ592314A (fr)
PA (1) PA8846201A1 (fr)
PE (1) PE20110546A1 (fr)
PL (1) PL2350026T3 (fr)
PT (1) PT2350026E (fr)
RS (1) RS53523B1 (fr)
SA (1) SA109300632B1 (fr)
SI (1) SI2350026T1 (fr)
TN (1) TN2011000199A1 (fr)
TW (2) TWI458716B (fr)
UA (1) UA103500C2 (fr)
UY (1) UY32190A (fr)
WO (1) WO2010046035A1 (fr)
ZA (1) ZA201103727B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011018517A1 (fr) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) * 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
DE102011080991A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
CA2848615C (fr) 2011-09-16 2020-02-25 Bayer Intellectual Property Gmbh Derives de 5-fluoropyrimidine disubstitues contenant un groupe sulfoximine
WO2013139734A1 (fr) * 2012-03-21 2013-09-26 Bayer Intellectual Property Gmbh Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl)pyrimidin-2-yl]amino}phényl)sulfoximide pour traiter des tumeurs spécifiques
CN107001341B (zh) * 2014-10-16 2020-08-07 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物
SI3849537T1 (sl) 2018-09-10 2025-03-31 Mirati Therapeutics, Inc. Kombinirane terapije
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
ES2253821T3 (es) 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
DE50213202D1 (de) 2001-05-29 2009-02-26 Bayer Schering Pharma Ag Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
US7504410B2 (en) 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2006034872A1 (fr) * 2004-09-29 2006-04-06 Bayer Schering Pharma Aktiengesellschaft 2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (fr) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Dérivés d'anilino-pyrimidine substitués par sulfone en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments

Also Published As

Publication number Publication date
KR20110069115A (ko) 2011-06-22
IL211713A (en) 2015-04-30
SA109300632B1 (ar) 2013-07-04
TW201020237A (en) 2010-06-01
WO2010046035A1 (fr) 2010-04-29
AU2009306733A1 (en) 2010-04-29
CA2739739C (fr) 2016-12-20
CN102197029A (zh) 2011-09-21
UY32190A (es) 2010-05-31
CA2739739A1 (fr) 2010-04-29
MX2011004238A (es) 2011-05-23
TW201444803A (zh) 2014-12-01
JP5564054B2 (ja) 2014-07-30
EA019230B1 (ru) 2014-02-28
US8735412B2 (en) 2014-05-27
AR074053A1 (es) 2010-12-22
CY1115590T1 (el) 2017-01-04
HN2011001019A (es) 2013-07-01
ECSP11010992A (es) 2011-05-31
TWI496774B (zh) 2015-08-21
RS53523B1 (sr) 2015-02-27
TN2011000199A1 (en) 2012-12-17
UA103500C2 (uk) 2013-10-25
ZA201103727B (en) 2014-11-26
BRPI0920112A2 (pt) 2015-12-22
CR20110210A (es) 2011-06-08
PE20110546A1 (es) 2011-08-12
EP2179991A1 (fr) 2010-04-28
PT2350026E (pt) 2014-09-12
AU2009306733B2 (en) 2015-11-12
TWI458716B (zh) 2014-11-01
SI2350026T1 (sl) 2014-10-30
MY155230A (en) 2015-09-30
DOP2011000107A (es) 2011-05-15
PL2350026T3 (pl) 2014-11-28
ES2499028T3 (es) 2014-09-26
AU2009306733C1 (en) 2016-07-14
EP2350026B1 (fr) 2014-06-18
EA201100623A1 (ru) 2011-12-30
NZ592314A (en) 2013-02-22
DK2350026T3 (da) 2014-09-15
JP2012506391A (ja) 2012-03-15
CO6361926A2 (es) 2012-01-20
EP2350026A1 (fr) 2011-08-03
CN102197029B (zh) 2014-05-14
CU20110088A7 (es) 2011-12-28
PA8846201A1 (es) 2010-05-26
US20110294838A1 (en) 2011-12-01
CU24052B1 (es) 2014-12-26
HRP20140830T1 (hr) 2014-11-21
IL211713A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
EA201170772A1 (ru) Органические соединения
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
TW201000488A (en) Heterocyclic derivatives
CU20110083A7 (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
EA201100447A1 (ru) Органические соединения
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
UA111579C2 (uk) ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
ATE554076T1 (de) Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
EA201290229A1 (ru) Производные спиролактама и их применение
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
ATE481395T1 (de) Cyclohexylderivate
EA201101703A1 (ru) 17β-АЛКИЛ-17α-ОКСИЭСТРАТРИЕНЫ